4.8 Article

The oncoprotein p28GANK establishes a positive feedback loop in β-catenin signaling

Journal

CELL RESEARCH
Volume 21, Issue 8, Pages 1248-1261

Publisher

SPRINGERNATURE
DOI: 10.1038/cr.2011.103

Keywords

p28(GANK); beta-catenin; E-cadherin; positive feedback loop; hepatocellular carcinoma

Categories

Funding

  1. Funds for Creative Research Groups of China [30921006]
  2. State Key Project for Liver Cancer [2008ZX10002]
  3. State Key Laboratory of Oncogenes and Related Genes [91-10-02, 91-10-03]
  4. National Natural Science Foundation of China [81001075, 81071778]

Ask authors/readers for more resources

p28(GANK) (also known as PSMD10 or gankyrin) is a novel oncoprotein that is highly expressed in hepatocellular carcinoma (HCC). Through its interaction with various proteins, p28(GANK) mediates the degradation of the tumor suppressor proteins Rb and p53. Although p53 was reported to downregulate beta-catenin, whether p28(GANK) is involved in the regulation of beta-catenin remains uncertain. Here we report that both growth factors and Ras upregulate p28(GANK) expression through the activation of the phosphoinositide 3-kinase-AKT pathway. Upregulation of p28(GANK) expression subsequently enhanced the transcription activity of beta-catenin. This effect was observed in p53-deficient cells, suggesting a p53-independent mechanism for the p28(GANK)-mediated activation of beta-catenin. p28(GANK) overexpression also reduced E-cadherin protein levels, leading to increased release of free beta-catenin into the cytoplasm from the cadherin- bound pool. Interestingly, exogenous expression of p28(GANK) resulted in elevated expression of the endogenous protein. We also observed that both beta-catenin and c-Myc were transcriptional activators of p28(GANK), and a correlation between p28(GANK) overexpression and c-Myc, cyclin D1 and beta-catenin activation in primary human HCC. Together, these results suggest that p28(GANK) expression is regulated by a positive feedback loop involving beta-catenin, which may play a critical role in tumorigenesis and the progression of HCC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Cardiac & Cardiovascular Systems

Cardiomyocyte-specific loss of RNA polymerase II subunit 5-mediating protein causes myocardial dysfunction and heart failure

Jian Zhang, Jingyi Sheng, Liwei Dong, Yinli Xu, Liming Yu, Yu Liu, Xiaoru Huang, Song Wan, Hui-Yao Lan, Huishan Wang

CARDIOVASCULAR RESEARCH (2019)

Article Gastroenterology & Hepatology

Six2 is negatively correlated with prognosis and facilitates epithelial-mesenchymal transition via TGF-β/Smad signal pathway in hepatocellular carcinoma

Zheng-Hua Wan, Yun-Han Ma, Tian-Yi Jiang, Yun-Kai Lin, Yuan-Yuan Shi, Ye-Xiong Tan, Li-Wei Dong, Hong-Yang Wang

HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2019)

Article Gastroenterology & Hepatology

RPB5-Mediating Protein Promotes Cholangiocarcinoma Tumorigenesis and Drug Resistance by Competing With NRF2 for KEAP1 Binding

Zheng-Hua Wan, Tian-Yi Jiang, Yuan-Yuan Shi, Yu-Fei Pan, Yun-Kai Lin, Yun-Han Ma, Chun Yang, Xiao-Fan Feng, Li-Feng Huang, Xiao-Ni Kong, Zhi-Wen Ding, Ye-Xiong Tan, Li-Wei Dong, Hong-Yang Wang

HEPATOLOGY (2020)

Article Cell Biology

Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing

Wen Wen, Wenru Su, Hao Tang, Wenqing Le, Xiaopeng Zhang, Yingfeng Zheng, Xiuxing Liu, Lihui Xie, Jianmin Li, Jinguo Ye, Liwei Dong, Xiuliang Cui, Yushan Miao, Depeng Wang, Jiantao Dong, Chuanle Xiao, Wei Chen, Hongyang Wang

CELL DISCOVERY (2020)

Article Biochemical Research Methods

Liquid Chromatography-Mass Spectrometry-Based Nontargeted Metabolomics Predicts Prognosis of Hepatocellular Carcinoma after Curative Resection

Qingqing Wang, Benzhe Su, Liwei Dong, Tianyi Jiang, Yexiong Tan, Xin Lu, Xinyu Liu, Xiaohui Lin, Guowang Xu

JOURNAL OF PROTEOME RESEARCH (2020)

Article Cell Biology

PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma

Tian-Yi Jiang, Yu-Fei Pan, Zheng-Hua Wan, Yun-Kai Lin, Bin Zhu, Zhen-gang Yuan, Yun-Han Ma, Yuan-Yuan Shi, Tian-Mei Zeng, Li-Wei Dong, Ye-Xiong Tan, Hong-Yang Wang

SCIENCE TRANSLATIONAL MEDICINE (2020)

Article Oncology

PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer

Tian-Yi Jiang, Xiao-Fan Feng, Zheng Fang, Xiao-Wen Cui, Yun-Kai Lin, Yu-Fei Pan, Chun Yang, Zhi-Wen Ding, Yong-Jie Zhang, Ye-Xiong Tan, Hong-Yang Wang, Li-Wei Dong

Summary: This study identified frequent alterations of PTEN in GBC, showing correlation with poor prognosis, and indicated proteasome inhibitor bortezomib as a promising therapeutic agent. Knockdown of PTEN increased bortezomib efficacy, and further evaluation using PDXs supported the utilization of bortezomib in PTEN-deficient GBC. Mechanistically, PTEN inhibited proteasome activity and bortezomib sensitivity through ARE-dependent transcriptional regulation, with involvement of the BACH1 transcriptional suppressor.

CANCER LETTERS (2021)

Review Biochemistry & Molecular Biology

Cytoskeleton-Associated Protein 4, a Promising Biomarker for Tumor Diagnosis and Therapy

Shuang-Xi Li, Juan Li, Li-Wei Dong, Zhi-Yong Guo

Summary: CKAP4 plays a crucial role in stabilizing the structure of the endoplasmic reticulum and acting as an activated receptor at the cell surface. Despite its involvement in tumorigenesis, the exact role of CKAP4 in tumor biology remains controversial due to its interaction with different ligands and signal transduction pathways in various microenvironments.

FRONTIERS IN MOLECULAR BIOSCIENCES (2021)

Article Biochemical Research Methods

Prognosis prediction of hepatocellular carcinoma after surgical resection based on serum metabolic profiling from gas chromatography-mass spectrometry

Chengnan Fang, Benzhe Su, Tianyi Jiang, Chao Li, Yexiong Tan, Qingqing Wang, Liwei Dong, Xinyu Liu, Xiaohui Lin, Guowang Xu

Summary: The study aimed to build prognostic models for hepatocellular carcinoma (HCC) patients based on serum metabolomics data, which demonstrated favorable ability to predict prognosis when combined with clinical staging system. Identified metabolic features were associated with mortality, recurrence, and metastasis, showing the power of metabolomics in screening HCC prognosis risk.

ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2021)

Article Cell Biology

RPRD1A stabilizes NRF2 and aggravates HCC progression through competing with p62 for TRIM21 binding

Xiaofan Feng, Tianyi Jiang, Chun Yang, Shujie Pang, Zhiwen Ding, Heping Hu, Hui Wang, Liwei Dong, Ning Yang

Summary: This study reveals that RPRD1A is highly expressed in hepatocellular carcinoma (HCC) and is correlated with aggressive clinicopathological features. RPRD1A competitively interacts with TRIM21 to inhibit the ubiquitination of p62 and increase its sequestration for Keap1, thus enhancing the nuclear translocation of NRF2 and promoting HCC development. Additionally, genetic knockdown of RPRD1A disturbs the redox homeostasis of cancer cells and sensitizes them to platinum-induced cell death.

CELL DEATH & DISEASE (2022)

Article Oncology

Metabolic Reprogramming and Risk Stratification of Hepatocellular Carcinoma Studied by Using Gas Chromatography-Mass Spectrometry-Based Metabolomics

Chengnan Fang, Hui Wang, Zhikun Lin, Xinyu Liu, Liwei Dong, Tianyi Jiang, Yexiong Tan, Zhen Ning, Yaorui Ye, Guang Tan, Guowang Xu

Summary: This study analyzed the metabolic reprogramming of hepatocellular carcinoma (HCC) using metabolomics and developed a metabolite classifier for HCC prognostic risk evaluation. The results showed that HCC is characterized by active glycolysis, enhanced fatty acid metabolism, and inhibited tricarboxylic acid cycle. Risk stratification based on differential metabolites revealed that tumors with higher levels of free fatty acids have a worse prognosis.

CANCERS (2022)

Article Cell Biology

Metabolic Reprogramming and Its Relationship to Survival in Hepatocellular Carcinoma

Qingqing Wang, Yexiong Tan, Tianyi Jiang, Xiaolin Wang, Qi Li, Yanli Li, Liwei Dong, Xinyu Liu, Guowang Xu

Summary: This study comprehensively analyzed the metabolic reprogramming in hepatocellular carcinoma (HCC) using metabolomics and lipidomics. The findings revealed enhanced aerobic glycolysis and de novo lipogenesis in HCC tissue, as well as repression of the urea cycle. Additionally, a differential correlation network was constructed, identifying key molecules related to the disease, and a panel of biomarkers was generated for prognostic risk stratification of HCC patients.

CELLS (2022)

Article Oncology

Gankyrin and TIGAR cooperatively accelerate glucose metabolism toward the PPP and TCA cycle in hepatocellular carcinoma

Chun Yang, Xiao-Wen Cui, Zhi-Wen Ding, Tian-Yi Jiang, Xiao-Fan Feng, Yu-Fei Pan, Yun-Kai Lin, Tai-Yu Shang, Qing Wang, Jian Pan, Jian Wang, Hong-Yang Wang, Li-Wei Dong

Summary: This study focused on the impact of gankyrin, a relatively specific oncogene in hepatocellular carcinoma (HCC), on glycolysis and mitochondrial homeostasis. It was found that gankyrin regulated the pentose phosphate pathway (PPP), tricarboxylic acid (TCA) cycle, and mitochondrial function and homeostasis, which played crucial roles in tumor development. Mechanistically, gankyrin was found to modulate HCC metabolic reprogramming via TIGAR.

CANCER SCIENCE (2022)

Article Cell Biology

The therapeutic effect of KSP inhibitors in preclinical models of cholangiocarcinoma

Yuanyuan Shi, Xiaowen Cui, Tianyi Jiang, Yufei Pan, Yunkai Lin, Xiaofan Feng, Zhiwen Ding, Chun Yang, Yexiong Tan, Hongyang Wang, Liwei Dong

Summary: In this study, several compound candidates were identified through a high-throughput drug screen as potential treatments for CCA. The KSP inhibitors showed significant cytotoxic effects on CCA cells, leading to mitotic arrest and cell death. Clinical data and the TCGA database also revealed that KIF11 expression was abundant in CCA tumor specimens and correlated with poor outcomes in CCA patients.

CELL DEATH & DISEASE (2022)

Article Cell Biology

PTEN deficiency facilitates gemcitabine efficacy in cancer by modulating the phosphorylation of PP2Ac and DCK

Tian-Yi Jiang, Xiao-Wen Cui, Tian-Mei Zeng, Yu-Fei Pan, Yun-Kai Lin, Xiao-fan Feng, Ye-Xiong Tan, Zhen-gang Yuan, Li-Wei Dong, Hong-Yang Wang

Summary: The deficiency of PTEN is correlated with the improved efficacy of gemcitabine-based chemotherapy in cholangiocarcinoma (CCA). PTEN deficiency or down-regulation enhances gemcitabine efficacy by directly binding to and dephosphorylating the catalytic subunit of protein phosphatase 2A (PP2Ac), leading to increased enzymatic activity and diminished phosphorylation of deoxycytidine kinase (DCK). Thus, PTEN deficiency and high phosphorylation of DCK can predict a better response to gemcitabine-based chemotherapy in CCA.

SCIENCE TRANSLATIONAL MEDICINE (2023)

No Data Available